Vyriad’s presentation will discuss progress in developing its highly targeted, efficient, serum-stable and durable lentiviral vector technology to deliver genetic payloads directly and specifically to CD3+ T cells. About Vyriad, Inc.Vyriad is a clinical-stage biotechnology company developing the next generation of targeted genetic therapies using engineered viruses, viral vectors and viral envelope glycoproteins to deliver genes directly to targeted cells. This targeting technology facilitates oncolytic virotherapy, in vivo gene therapies and gene editing applications. Vyriad is a privately held company based in Rochester, Minnesota. Vyriad Media Contact:Scott BeckVyriad, Inc.[email protected]View original content to download multimedia:https://www.prnewswire.com/news-releases/vyriad-announces-oral-presentation-at-the-65th-american-society-of-hematology-annual-meeting-301983710.htmlSOURCE Vyriad, Inc.Disclaimer: The above press release comes to you under an arrangement with PR Newswire.

Source: The Bubble November 09, 2023 17:14 UTC